La “FUNDACION ESPAÑOLA PARA LA CURACION DE LA LEUCEMIA MIELOIDE CRONICA”, participa activamente en el avance científico de la curación de la enfermedad, actualmente, la investigación se centra en la búsqueda de otros genes que pueden influir en el desarrollo de la enfermedad.</p align=»justify»>
LISTADO DE PUBLICACIONES MÁS RELEVANTES DEL GELMC (Grupo Español de Leucemia Mieloide Crónica) entre 2016 y 2018.
- Chronic myeloid leukaemia in Spain: Its presentation characteristics have changed. Spanish sectionof the EUTOS population-based registry. Osorio S, Casado LF, Giraldo P, Maestro B, Andrade M, Redondo S, García-Gutiérrez V, Ayala R, Garcia N, Steegmann JL. Rev Clin Esp. 2016 Aug-Sep; 216(6):293-300. Epub 2016 Apr 6. English, Spanish. PMID: 27061504. DOI:10.1016/j.rce.2016.03.001
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE. Leukemia. 2016 Aug; 30(8):1648-71. Epub 2016 Apr 28. Review. PMID: 27121688. PMCID: PMC4991363. DOI: 10.1038/leu.2016.104
- [Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinaryperspective, and proposing action protocol by consensus meeting]. García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL. Med Clin (Barc). 2016 Jun 17; 146(12):561.e1-8. Epub 2016 20. Spanish. PMID: 27107729. DOI:10.1016/j.medcli.2016.02.022
- Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Cervantes F, Correa JG, Pérez I, García-Gutiérrez V, Redondo S, Colomer D, Jiménez-Velasco A, Steegmann JL, Sánchez-Guijo F, Ferrer-Marín F, Pereira A, Osorio S; CML Spanish Group (GELMC). Ann Hematol. 2017 Jan; 96(1):81-85. Epub 2016 Oct 8. PMID: 27717993. DOI:10.1007/s00277-016-2839-z
- A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redondo S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC). PLoS One. 2017 Mar 9; 12(3):e0173532. eCollection 2017. PMID: 28278193. PMCID:PMC5344481 DOI:10.1371/journal.pone.0173532
- PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. Alonso-Dominguez JM, Casado LF, Anguita E, Gomez-Casares MT, Buño I, Ferrer-Marín F, Arenas A, Del Orbe R, Ayala R, Llamas P, Salgado RN, Osorio S, Sanchez-Godoy P, Burgaleta C, Mahíllo-Fernández I, Garcia-Gutierrez V, Steegmann JL, Martinez-Lopez J.. PLoS One. 2017 Jul 13; 12(7):e0181366. doi: 10.1371/journal.pone.0181366. eCollection 2017. PMID: 28704552. PMCID:PMC5509313 DOI:10.1371/journal.pone.0181366
- An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. J Cancer Res Clin Oncol. 2017 Oct; 143(10):2059-2066. Epub 2017 May 27. PMID:28551768 PMCID:PMC5653730 DOI:10.1007/s00432-017-2445-z. Erratum in: Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Steegmann JL et al. J Cancer Res Clin Oncol. (2018) Jan; 144(1):187-188. PMID:29063181. PMCID:PMC5756548 DOI:10.1007/s00432-017-2532-1
- Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC). Ann Hematol. 2018 Nov; 97(11):2089-2098. Epub 2018 Jun 28. PMID: 29955943. DOI:10.1007/s00277-018-3413-7
- Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Blood Cancer J. 2018 Dec 2; 8(10):91. PMID: 30504932. PMCID:PMC6275158 DOI:10.1038/s41408-018-0125-0
- Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M. Biochem Pharmacol. 2018 Oct; 156:248-264. Epub 2018 Aug 22. PMID:30142322. DOI:10.1016/j.bcp.2018.08.031